Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28451515 | 0.92 | TSHR (0.40) | — | |
| SCHEMBL10516000 | 0.91 | SQOR (0.35) | — | |
| SCHEMBL3709877 | 0.91 | APP (0.33) | — | |
| SCHEMBL28447850 | 0.91 | MEN1 (0.39) | — | |
| SCHEMBL10107622 | 0.91 | CTSK (0.31) | — | |
| SCHEMBL1269231 | 0.90 | MAPK1 (0.39) | ESR1ESR2 | |
| SCHEMBL28454941 | 0.89 | CA12 (0.38) | — | |
| SCHEMBL6724604 | 0.85 | CASR (0.37) | — | |
| SCHEMBL5185987 | 0.81 | ESR2 (0.41) | ESR2 | |
| SCHEMBL20176055 | 0.77 | MEN1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1296945-B1 | SULFONAMIDE DERIVATIVES | LILLY CO ELI (US) | 2004-08-04 | — | — | EP | disclosed |
| US-6703425-B2 | ADMINISTERING GLUTAMATE RECEPTOR POTENTIATOR TO TREAT PSYCHOLOGICAL AND NERVOUS SYSTEM DISORDERS | ELI LILLY AND COMPANY | 2004-03-09 | — | — | US | disclosed |
| US-20030229102-A1 | Sulfonamide derivatives | ELI LILLY AND COMPANY | 2003-12-11 | — | — | US | disclosed |
| EP-1296945-A1 | SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2003-04-02 | — | — | EP | disclosed |
| WO-2001096289-A1 | SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229102-A1 | Sulfonamide derivatives | GRIN1, GRIN2A, SLC1A2 | KIF11 3122/4885ESR1 3585/4885ESR2 2364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.